

Characteristics and Treatment Patterns of Early-Stage Melanoma: Results from a Multi-site Chart Review

Drugs – Real World Outcomes

Collin M. Costello¹, Maria L. Wei², James Isaacs³, Elizabeth M. Gaughan⁴, Adina Greene¹, Alexandra So², Xiaochen Zhong², Jara Majuelos-Melguizo⁵, Kavita Gandhi⁵, Claudia Rey⁵, Alicia Delibes⁵, Rosemarie Barnett⁵, Mizuho Fukunaga-Kalabis⁶, Nawab Qizilbash^{5,7}, Irene Shui⁶, Xiang-Lin Tan⁶.

¹ Mayo Clinic, Scottsdale, AZ, USA

² University of California San Francisco, San Francisco, CA, USA; San Francisco VA Health Care System, San Francisco, CA, USA

³ Cleveland Clinic, Cleveland, OH, USA

⁴ University of Virginia Cancer Center, Charlottesville, VA, USA

⁵ OXON Epidemiology, Madrid, Spain

⁶ Merck & Co., Inc., Rahway, NJ, USA

⁷ London School of Hygiene & Tropical Medicine, London, UK

Corresponding author:

XiangLin Tan, MD, PhD, Email: xianglin.tan@merck.com.

Characteristics and Treatment Patterns of Early-Stage Melanoma: Results from a Multi-site Chart Review_Supplementary information

Supplementary tables

Supplementary Table 1. Proportions of Newly Diagnosed Patients with Cutaneous Stage I and II Melanoma in the Aggregate Cohort and by year

	Aggregate Cohort	2018	2019	2020	2021	2022
Stage N (%)	N = 7285	N = 1452	N = 1609	N = 1324	N = 1452	N = 1448
Stage IA	4,909 (67.4)	943 (64.9)	1,099 (68.3)	902 (68.1)	967 (66.6)	998 (68.9)
Stage IB	1,023 (14.0)	228 (15.7)	228 (14.2)	182 (13.8)	195 (13.4)	190 (13.1)
Stage IIA	459 (6.3)	97 (6.7)	99 (6.2)	91 (6.9)	83 (5.7)	89 (6.2)
Stage IIB	387 (5.3)	87 (6.0)	78 (4.8)	61 (4.6)	88 (6.1)	73 (5.0)
Stage IIC	215 (3.0)	41 (2.8)	43 (2.7)	36 (2.7)	56 (3.9)	39 (2.7)
Unknown	292 (4.0)	56 (3.9)	62 (3.9)	52 (3.9)	63 (4.3)	59 (4.1)

Characteristics and Treatment Patterns of Early-Stage Melanoma: Results from a Multi-site Chart Review_Supplementary information

Supplementary Table 2. Composition of lines of treatment, stratified by LOT number


	Overall	First LOT	Second LOT	Third LOT
Number of patients receiving each LOT N (%)	398 (100)	394 (100)	64 (100)	25 (100)
Composition of the LOTs ^a				
Surgery	270 (67.8)	268 (68.0)	6 (9.4)	4 (16.0)
Surgery + Watchful waiting	118 (29.6)	118 (29.9)	4 (6.3)	1 (4.0)
Systemic drug therapy	34 (8.5)	0 (0.0)	29 (45.3)	13 (52.0)
Watchful waiting	22 (5.5)	2 (0.5)	14 (21.9)	5 (20.0)
Surgery + Systemic drug therapy	10 (2.5)	6 (1.5)	5 (7.8)	0 (0.0)
Radiotherapy	6 (1.5)	0 (0.0)	3 (4.7)	1 (4.0)
Radiotherapy + Systemic drug therapy	5 (1.3)	0 (0.0)	3 (4.7)	1 (4.0)

Abbreviation: LOT, Line of Treatment.


^a Among the total number of LOTs reported. Only those LOTs with a frequency at least 1% appear in the Table.

Characteristics and Treatment Patterns of Early-Stage Melanoma: Results from a Multi-site Chart Review_Supplementary information

Supplementary figures




Supplementary Fig. S 1. Sankey Plot in Stage IB in patients with more than one LOT (n=20)
Abbreviation: SDT, Systemic Drug Therapy; Radio, Radiotherapy; Watchful, Watchful waiting.




Supplementary Fig. S 2. Sankey Plot in Stage IIA in patients with more than LOT (n= 19)
Abbreviation: SDT, Systemic Drug Therapy; Radio, Radiotherapy; Watchful, Watchful waiting.

Characteristics and Treatment Patterns of Early-Stage Melanoma: Results from a Multi-site Chart Review_Supplementary information



Supplementary Fig. S 3. Sankey Plot in Stage IIB in patients with more than one LOT (n= 15)
Abbreviation: SDT, Systemic Drug Therapy; Radio, Radiotherapy; Watchful, Watchful waiting.



Supplementary Fig. S 4. Sankey Plot in Stage IIC in patients with more than one LOT (n=10)
Abbreviation: SDT, Systemic Drug Therapy; Radio, Radiotherapy; Watchful, Watchful waiting.